                         SEQUENCE LISTING

<110>  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE 
       SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
       BAKER IDI HEART & DIABETES INSTITUTE
       Remaley, Alan  T.
       Sviridov, Dmitri
       Sethi, Amar  A.
 
<120>  SYNTHETIC APOA-1 MIMETIC AMPHIPATHIC PEPTIDES AND METHODS OF USE THEREOF

<130>  4239-82292-02

<150>  US 61/265291
<151>  2009-11-30

<160>  40    

<170>  PatentIn version 3.5

<210>  1
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide 5A

<400>  1

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu 
1               5                   10                  15      


Ala Phe Pro Asp Trp Ala Lys Ala Ala Tyr Asp Lys Ala Ala Glu Lys 
            20                  25                  30          


Ala Lys Glu Ala 
        35      


<210>  2
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic prototypical ELK peptide

<400>  2

Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  3
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-3E3K

<400>  3

Glu Glu Leu Lys Glu Lys Leu Glu Glu Leu Lys Glu Lys Leu Glu Glu 
1               5                   10                  15      


Lys Leu Pro Glu Glu Leu Lys Glu Lys Leu Glu Glu Leu Lys Glu Lys 
            20                  25                  30          


Leu Glu Glu Lys Leu 
        35          


<210>  4
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELK-3E3K3A

<400>  4

Glu Glu Leu Lys Ala Lys Leu Glu Glu Leu Lys Ala Lys Leu Glu Glu 
1               5                   10                  15      


Lys Leu Pro Glu Glu Leu Lys Ala Lys Leu Glu Glu Leu Lys Ala Lys 
            20                  25                  30          


Leu Glu Glu Lys Leu 
        35          


<210>  5
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-2A

<400>  5

Glu Lys Leu Lys Ala Leu Leu Glu Lys Leu Leu Ala Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Leu Lys Ala Leu Leu Glu Lys Leu Leu Ala Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  6
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-1W

<400>  6

Glu Trp Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Trp Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  7
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-2F

<400>  7

Glu Lys Phe Lys Glu Leu Leu Glu Lys Phe Leu Glu Lys Phe Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Phe Lys Glu Leu Leu Glu Lys Phe Leu Glu Lys 
            20                  25                  30          


Phe Lys Glu Leu Leu 
        35          


<210>  8
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-1L1K

<400>  8

Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Leu Leu Lys Lys 
1               5                   10                  15      


Leu Leu Pro Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Leu 
            20                  25                  30          


Leu Lys Lys Leu Leu 
        35          


<210>  9
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-1K1A1E

<400>  9

Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Lys Ala Lys Leu Glu Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Lys Ala Lys 
            20                  25                  30          


Leu Glu Glu Leu Leu 
        35          


<210>  10
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-1A

<400>  10

Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Ala Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Ala Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  11
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-1F

<400>  11

Glu Lys Phe Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Phe Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  12
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-2A2K2E

<400>  12

Glu Lys Leu Lys Ala Lys Leu Glu Glu Leu Lys Ala Lys Leu Glu Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Leu Lys Ala Lys Leu Glu Glu Leu Lys Ala Lys 
            20                  25                  30          


Leu Glu Glu Leu Leu 
        35          


<210>  13
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  sythetic peptide ELK-3E3K

<400>  13

Glu Glu Leu Lys Glu Leu Leu Lys Glu Leu Leu Lys Lys Leu Glu Lys 
1               5                   10                  15      


Leu Leu Pro Glu Leu Lys Glu Leu Leu Lys Glu Leu Leu Lys Lys Leu 
            20                  25                  30          


Glu Lys Leu Leu 
        35      


<210>  14
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-2E2K

<400>  14

Glu Glu Leu Lys Lys Leu Leu Glu Glu Leu Leu Lys Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Pro Glu Glu Leu Lys Lys Leu Leu Glu Glu Leu Leu Lys Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  15
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-PA

<400>  15

Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Ala Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys 
            20                  25                  30          


Leu Lys Glu Leu Leu 
        35          


<210>  16
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-P2A

<400>  16

Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Lys Glu 
1               5                   10                  15      


Leu Leu Ala Ala Glu Lys Leu Lys Glu Leu Leu Glu Lys Leu Leu Glu 
            20                  25                  30          


Lys Leu Lys Glu Leu Leu 
        35              


<210>  17
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELK-A

<400>  17

Glu Lys Leu Lys Ala Lys Leu Glu Glu Leu Lys Ala Lys Leu Glu Glu 
1               5                   10                  15      


Leu Leu Pro Glu Lys Ala Lys Ala Ala Leu Glu Glu Ala Lys Ala Lys 
            20                  25                  30          


Ala Glu Glu Leu Ala 
        35          


<210>  18
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide ELKA-CH2

<400>  18

Glu Lys Leu Lys Ala Lys Leu Glu Glu Leu Lys Ala Lys Leu Glu Glu 
1               5                   10                  15      


Leu Leu Pro Glu His Ala Lys Ala Ala Leu Glu Glu Ala Lys Cys Lys 
            20                  25                  30          


Ala Glu Glu Leu Ala 
        35          


<210>  19
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide 5A-CH1

<400>  19

Asp His Leu Lys Ala Phe Tyr Asp Lys Val Ala Cys Lys Leu Lys Glu 
1               5                   10                  15      


Ala Phe Pro Asp Trp Ala Lys Ala Ala Tyr Asp Lys Ala Ala Glu Lys 
            20                  25                  30          


Ala Lys Glu Ala Ala 
        35          


<210>  20
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223> synthetic peptide 5A-CH2

<400>  20

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu 
1               5                   10                  15      


Ala Phe Pro Asp His Ala Lys Ala Ala Tyr Asp Lys Ala Ala Cys Lys 
            20                  25                  30          


Ala Lys Glu Ala Ala 
        35          


<210>  21
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide 5A-C1

<400>  21

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Cys Lys Leu Lys Glu 
1               5                   10                  15      


Ala Phe Pro Asp Trp Ala Lys Ala Ala Tyr Asn Lys Ala Ala Glu Lys 
            20                  25                  30          


Ala Lys Glu Ala Ala 
        35          


<210>  22
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide 5A-H1

<400>  22

Asp His Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu 
1               5                   10                  15      


Ala Phe Pro Asp Trp Ala Lys Ala Ala Tyr Asp Lys Ala Ala Glu Lys 
            20                  25                  30          


Ala Lys Glu Ala 
        35      


<210>  23
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic cell recognition peptide sequence

<400>  23

Arg Lys Asn Arg 
1               


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide cell recognition sequence

<400>  24

Lys Lys Trp Val Arg 
1               5   


<210>  25
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide cell recognition sequence

<400>  25

Arg Gly Asp 
1           


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide cell recognition sequence

<400>  26

Asp Val Glu Trp Val Asp Val Ser Tyr 
1               5                   


<210>  27
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic internalization peptide

<400>  27

Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln 
1               5                   10          


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic internalization peptide

<400>  28

Arg Arg Arg Gln Arg Arg Lys Lys Arg 
1               5                   


<210>  29
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  RRPXR


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring amino acid

<400>  29

Arg Arg Pro Xaa Arg 
1               5   


<210>  30
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic internalization peptide

<400>  30

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210>  31
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic neutral cholesterol esterase activation peptide

<400>  31

Gly His Glu Asp Thr Met Ala Asp Gln Glu Ala Asn Arg His Gly Arg 
1               5                   10                  15      


Ser Gly Gly Asp Pro Asn Tyr Tyr Arg Pro Pro Gly Gly Tyr 
            20                  25                  30  


<210>  32
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic inhibitory ACAT peptide

<400>  32

Gly Phe Phe Ser Phe Ile Gly Glu Ala Phe Gln Gly Ala Gly Asp Met 
1               5                   10                  15      


Trp Arg Ala Tyr 
            20  


<210>  33
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic enhancer of liver affinity peptide

<400>  33

Lys Ala Glu Tyr Lys Lys Asn Lys His Arg His 
1               5                   10      


<210>  34
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic enhancer of liver affinity peptide

<400>  34

Tyr Thr Arg Leu Thr Arg Lys Arg Gly Leu Lys 
1               5                   10      


<210>  35
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-oxidant peptide

<400>  35

Asp Trp Leu Lys Ala Phe Tyr Cys Lys Val Ala Glu Lys Leu Lys Glu 
1               5                   10                  15      


Ala Phe 
        


<210>  36
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-oxidant peptide

<400>  36

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Cys 
1               5                   10                  15      


Ala Phe 
        


<210>  37
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-oxidant peptide

<400>  37

Tyr Ser Asp Gly Leu Arg Gln Cys Leu Ala Ala Arg Leu Asp Ala Leu 
1               5                   10                  15      


Lys Asp Arg 
            


<210>  38
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy metal chelation peptide

<400>  38

His His His His His His 
1               5       


<210>  39
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy metal chelation peptide

<400>  39

Phe Gln Trp Gln Arg Asn Ile Arg Lys Val Arg 
1               5                   10      


<210>  40
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic lipoprotein lipase activation peptide


<220>
<221>  misc_feature
<222>  (1)..(2)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (4)..(5)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (7)..(8)
<223>  Xaa can be any naturally occurring amino acid

<400>  40

Xaa Xaa Tyr Xaa Xaa Ile Xaa Xaa Asp Gln 
1               5                   10  


